Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BV100 plus polymyxin B versus colistin plus ampicillin/sulbactam for carbapenem-resistant Acinetobacter pneumonia
2025-524092-23-00Phase 3Authorised
- Sponsor
- BioVersys AG
- Start
- Jul 2026
- Modality
- Peptides, Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised trial of rifabutin, polymyxin B, colistin and ampicillin + sulbactam in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) (2 arms), sponsored by BioVersys AG. Primary endpoint: 28-day all-cause mortality in the CRABC modified microbiological intent-to-treat population in Part A. Planned start Jul 2026; status: authorised.
02
Drugs
rifabutinpolymyxin Bcolistinampicillin + sulbactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2025-524092-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524092-23-00.